The ACSL4 Knockout SK-OV-3 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-OV-3 human ovarian adenocarcinoma cell line, in which the ACSL4 gene has been disrupted to generate a loss-of-function model. This polyclonal population consists of a heterogeneous pool of cells harboring diverse editing outcomes at the ACSL4 locus, providing a robust tool for studying gene function without the clonal selection bias inherent in single-cell-derived lines. The use of CRISPR/Cas9-mediated gene disruption ensures stable, heritable inactivation of ACSL4, enabling researchers to dissect its biological roles in a physiologically relevant cancer cell background.
SK-OV-3 is a well-characterized epithelial cell line derived from the ascites of a patient with ovarian adenocarcinoma. Notably, these cells harbor a homozygous deletion of the TP53 gene, rendering them p53-null, and exhibit moderate resistance to cisplatin, a standard chemotherapeutic agent. They also possess an autocrine signaling loop involving endothelin-3 (ET-3) and its receptor endothelin B receptor (ETBR), which contributes to their proliferative and survival capacities. This genetic and signaling context makes SK-OV-3 a valuable model for investigating mechanisms of drug resistance and tumor progression in ovarian cancer.
ACSL4 encodes a long-chain fatty acyl-CoA synthetase that preferentially activates arachidonic acid and other polyunsaturated fatty acids, playing a pivotal role in phospholipid remodeling and ferroptosis regulation. Transcriptionally controlled by SREBP1 and PPAR??, and modulated by PKC and NF-??B signaling, ACSL4 catalyzes the formation of fatty acyl-CoAs that serve as substrates for incorporation into membrane phospholipids by LPCAT3. This process enriches membranes with oxidizable lipids, which are subsequently peroxidized by lipoxygenases such as ALOX15. The accumulation of lipid peroxides triggers ferroptosis, an iron-dependent cell death pathway that is negatively regulated by GPX4. Thus, ACSL4 functions upstream of lipid peroxidation cascades, integrating metabolic and stress signals to determine cellular sensitivity to ferroptosis.
In the context of SK-OV-3 cells, loss of ACSL4 expression is expected to blunt the incorporation of polyunsaturated fatty acids into membrane phospholipids, thereby reducing the availability of substrates for lipid peroxidation and conferring resistance to ferroptosis inducers like erastin or RSL3. Given the p53-null status and cisplatin resistance of SK-OV-3, this knockout model is particularly relevant for exploring the interplay between ferroptosis susceptibility and drug resistance in ovarian cancer. It allows direct interrogation of how ACSL4-dependent lipid remodeling impacts cell fate under oxidative stress and chemotherapeutic pressure, potentially revealing targetable vulnerabilities.
Research applications of this polyclonal knockout model are extensive and include dose?Cresponse studies with ferroptosis activators (e.g., erastin, RSL3) coupled with lipid peroxidation measurements using C11-BODIPY or malondialdehyde assays. Western blotting and RT-qPCR can confirm ACSL4 disruption, while cell viability, invasion, and migration assays enable phenotypic characterization. Moreover, combining cisplatin treatment with ferroptosis modulation may uncover synergistic or antagonistic interactions, informing therapeutic strategies. For additional technical information or to inquire about this product, please contact Ascent Research.
